Interleukin (IL)-12 and IL-23 are implicated in the pathogenesis of psoriasis and new IL-12/23 inhibitors are currently being studied for psoriasis treatment.
Objective
To review the literature and provide an update on the current use of anti-IL-12/IL-23 therapies for psoriasis, with special emphasis on risks and benefits.
Methods
A PubMed search was performed to identify articles in English with key words “Ustekinumab and psoriasis,” “IL-12 and IL-23 and psoriasis,” “ABT-874 and psoriasis,” “IL-12/23 monoclonal antibody,” “IL-12/23 antibody” and “CNTO-1275.” Supplemental methods included Google Scholar, article reference lists and scholarly posters.
Results
Anti-IL-12/23 therapies may be more effective for psoriasis treatment than concurrent biologics. However, there is a potential risk of compromising cancer surveillance mechanisms through blocking IL-12.
Limitations
More research is needed into the long-term effects of anti-IL-12/23 agents.
Conclusions
Convenient dosing of ustekinumab and greater efficacy make the anti- IL-12/23 agents a promising therapeutic option.
NairR.P., RuetherA., StuartP.E., JenischS., TejasviT., HiremagaloreR.Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol.2008; 128: 1653–61.
2.
TortiD.C., FeldmanS.R.Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol.2007; 57: 1059–68.
3.
DuerrR.H., TaylorK.D., BrantS.R., RiouxJ.D., SilverbergM.S., DalyM.J.A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science.2006; 314: 1461–3.
4.
CargillM., SchrodiS.J., ChangM., GarciaV.E., BrandonR., CallisK.P.A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet.2007; 80: 273–90.
5.
CaponF., DiM.P., SzaubJ., PrescottN.J., DunsterC., BaumberL.Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet.2007; 122: 201–6.
6.
ChangY.T., ChouC.T., YuC.W., LinM.W., ShiaoY.M., ChenC.C.Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol.2007; 156: 899–905.
7.
FilerC., HoP., SmithR.L., GriffithsC., YoungH.S., WorthingtonJ.Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum.2008; 58: 3705–9.
8.
GordonK., TschenE., KormanN.A Phase II study of STA-5326, an oral IL12 and IL3 inhibitor, in patients with mode rate-to-severe chronic plaque psoriasis (CPP). 4th International Congress. The Royal College of Physicians. 2005. 12-1-2005. Ref Type: Conference Proceeding.
9.
WuJ.J.Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials. J Am Acad Dermatol.2008; 58: 1083.
10.
KimballA.B., GordonK.B., LangleyR.G., MenterA., ChartashE.K., ValdesJ.Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol.2008; 144: 200–7.
11.
LeonardiC.L., KimballA.B., PappK.A., YeildingN., GuzzoC., WangY.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet.2008; 371: 1665–74.
12.
PappK.A., LangleyR.G., LebwohlM., KruegerG.G., SzaparyP., YeildingN.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet.2008; 371: 1675–84.
FieschiC, CasanovaJ.The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol.2003; 33: 461–1464.
15.
ZhuY., HuC., LuM., LiaoS., MariniJ.C., YohrlingJ.Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40 in patients with moderate to severe plaque psoriasis. J Clin Pharmacol.2009; 49: 162–75.
16.
RichP.Phase 3 Study of ustekinumab in psoriasis: improvement in nail psoriasis. EADV.2008. 9-13-2008. Ref Type: Conference Proceeding.
17.
CuchacovichR.S., EspinozaL.R.Ustekinumab for psoriatic arthritis. Lancet.2009; 373: 605–6.
18.
LeonardiC., PappK., KunynetzR., SzaparyP., LiS., YeildingN.Efficacy and safety of ustekinumab in patients with moderate-to-severe psoriasis and concomitant psoriatic arthritis: Results from phase 3 randomized clinical trials. Poster at 2nd World Psoriasis & Psoriatic Arthritis Conference 2009, Stockholm, Sweden. 2009. Ref Type: Conference Proceeding.
19.
GottliebA., MenterA., MendelsohnA., ShenY.K., LiS., GuzzoC.Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet.2009; 373: 633–40.
20.
GottliebA.B., MenterA., MendelsohnA., ShenY., LiS., KavanaughA.Efficacy of ustekinumab, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis patients with baseline C-reactive protein >/=0.4 versus <0.4mg/dL: results of a post hoc analysis of data from a phase 2, randomized, double-blind, placebo-controlled study. Poster at 2nd World Psoriasis & Psoriatic Arthritis Conference. 2009, Stockholm, Sweden. Ref Type: Conference Proceeding.
21.
GriffithsC., StroberB., van de KerkhofP.C., HoV., GuzzoC., YeildingN.A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe psoriasis. Presented at: 2008 European Academy of Dermatology & Venereology (EADV), Paris, Poster FP1336. Ref Type: Conference Proceeding.
